自体骨髓间充质干细胞治疗扩张性心肌病:安全和有效性的Meta分析
发布时间：2018-08-06 18:45
【摘要】：背景:自体骨髓间充质干细胞已被用于扩张性心肌病的临床治疗,但其安全性和有效性存在争议。目的:运用Meta分析方法评价自体骨髓间充质干细胞移植治疗扩张性心肌病的安全性和有效性。方法:系统检索Pub Med、Cochrane Library(2016年第2期)、Embase、CNKI、CBM、维普、万方数据库中,有关自体骨髓间充质干细胞移植与常规药物治疗扩张性心肌病的临床随机对照试验。运用R3.1.0软件对两种治疗后的左室射血分数、左室舒张末期内径、6 min步行距离、心肌灌注缺损面积百分比、治疗及随访过程中患者死亡率、恶性心律失常发生率及心脏移植率进行Meta分析。结果与结论:纳入7个随机对照试验,合计341例扩张性心肌病患者。Meta分析结果显示:与常规药物疗法相比,自体骨髓间充质干细胞移植能增加扩张性心肌病患者左心室射血分数[1个月:MD=3.02,95%CI(1.55,4.49);3个月:MD=4.38,95%CI(3.55,5.52);6个月:MD=6.47,95%CI(4.78,8.15);≥12个月:MD=8.23,95%CI(5.15,9.19)],降低治疗3个月后的左室舒张末期内径[3个月:MD=-0.65,95%CI(-0.72,-0.59);6个月:MD=-0.12,95%CI(-0.21,-0.03);≥12个月:MD=-0.19,95%CI(-0.24,-0.13)],增加治疗6个月后6 min步行距离[6个月:MD=87.70,95%CI(51.55,123.85);≥12个月:MD=143.83,95%CI(122.73,164.93)],降低治疗3个月的心肌灌注缺血面积百分比[MD=-3.56,95%CI(-5.57,-1.55)],降低治疗及随访期间死亡率[RR=0.46,95%CI(0.24,0.89)];两种治疗在降低恶性心律失常及心脏移植率上无明显差异。研究结果提示,自体骨髓间充质干细胞移植治疗扩张性心肌病疗效优于常规药物疗法,且安全性良好。
[Abstract]:Background: autologous bone marrow mesenchymal stem cells have been used in the treatment of dilated cardiomyopathy, but their safety and efficacy are controversial. Objective: to evaluate the safety and efficacy of autologous bone marrow mesenchymal stem cell transplantation in the treatment of dilated cardiomyopathy by Meta analysis. Methods: the clinical randomized controlled trials of autologous bone marrow mesenchymal stem cell transplantation and routine drug therapy for dilated cardiomyopathy were systematically searched in Pub Meda Cochrane Library (second issue 2016). The left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVED) walking distance of 6 min, the percentage of myocardial perfusion defect area and mortality during treatment and follow-up were measured by R3.1.0 software. The incidence of malignant arrhythmia and the rate of cardiac transplantation were analyzed by Meta. Results and conclusion: a total of 341 patients with dilated cardiomyopathy were enrolled in 7 randomized controlled trials. 鑷綋楠ㄩ珦闂村厖璐ㄥ共缁嗚優绉绘鑳藉鍔犳墿寮犳，
本文编号：2168656
[Abstract]:Background: autologous bone marrow mesenchymal stem cells have been used in the treatment of dilated cardiomyopathy, but their safety and efficacy are controversial. Objective: to evaluate the safety and efficacy of autologous bone marrow mesenchymal stem cell transplantation in the treatment of dilated cardiomyopathy by Meta analysis. Methods: the clinical randomized controlled trials of autologous bone marrow mesenchymal stem cell transplantation and routine drug therapy for dilated cardiomyopathy were systematically searched in Pub Meda Cochrane Library (second issue 2016). The left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVED) walking distance of 6 min, the percentage of myocardial perfusion defect area and mortality during treatment and follow-up were measured by R3.1.0 software. The incidence of malignant arrhythmia and the rate of cardiac transplantation were analyzed by Meta. Results and conclusion: a total of 341 patients with dilated cardiomyopathy were enrolled in 7 randomized controlled trials. 鑷綋楠ㄩ珦闂村厖璐ㄥ共缁嗚優绉绘鑳藉鍔犳墿寮犳，
本文编号：2168656
本文链接：https://www.wllwen.com/yixuelunwen/xxg/2168656.html
最近更新
教材专著
